By Fineline Cube 
China-based Brii Biosciences Ltd (HKG: 2137) announced a licensing agreement with compatriot firm Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) for its investigational drug BRII-693. This strategic partnership aims to advance the development and commercialization of BRII-693 in Greater China.
Licensing Agreement Details
Under the agreement, Joincare Pharma secures exclusive rights for research and development, regulatory filing, and commercialization of BRII-693 in Greater China. Brii Biosciences has received an undisclosed upfront payment and will be eligible for additional development and commercialization milestone payments. The company will also receive tiered royalties based on the net sales of the product.
BRII-693: Targeting Multidrug-Resistant Infections
BRII-693 is an investigational novel synthetic lipopeptide designed to treat critically ill patients with multidrug-resistant and extensively drug-resistant (MDR/XDR) Gram-negative bacterial infections. These infections are particularly caused by carbapenem-resistant Acinetobacter baumannii (CRAB), Pseudomonas aeruginosa (CRPA), and Enterobacteriaceae (CRE). BRII-693 has previously demonstrated favorable safety, tolerability, and pharmacokinetic profiles in Phase I studies.-Fineline Info & Tech